Quarterly Report (10-q)
April 21 2022 - 8:36AM
Edgar (US Regulatory)
0001589150
false
09/30
2022
Q2
0001589150
2021-10-01
2022-03-31
0001589150
2022-04-07
0001589150
2022-03-31
0001589150
2021-09-30
0001589150
us-gaap:SeriesAPreferredStockMember
2022-03-31
0001589150
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2022-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesMMember
2022-03-31
0001589150
RGBP:SeriesMMember
2021-09-30
0001589150
RGBP:SeriesNCMember
2022-03-31
0001589150
RGBP:SeriesNCMember
2021-09-30
0001589150
2022-01-01
2022-03-31
0001589150
2021-01-01
2021-03-31
0001589150
2020-10-01
2021-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2020-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2020-09-30
0001589150
RGBP:SeriesNCPreferredStockMember
2020-09-30
0001589150
us-gaap:CommonStockMember
2020-09-30
0001589150
RGBP:SeriesMPreferredStockMember
2020-09-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-09-30
0001589150
us-gaap:RetainedEarningsMember
2020-09-30
0001589150
RGBP:ContributedCapitalMember
2020-09-30
0001589150
2020-09-30
0001589150
RGBP:PreferredStockSeriesAMember
2020-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2020-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2020-12-31
0001589150
us-gaap:CommonStockMember
2020-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2020-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001589150
us-gaap:RetainedEarningsMember
2020-12-31
0001589150
RGBP:ContributedCapitalMember
2020-12-31
0001589150
2020-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesNCPreferredStockMember
2021-09-30
0001589150
us-gaap:CommonStockMember
2021-09-30
0001589150
RGBP:SeriesMPreferredStockMember
2021-09-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001589150
us-gaap:RetainedEarningsMember
2021-09-30
0001589150
RGBP:ContributedCapitalMember
2021-09-30
0001589150
RGBP:PreferredStockSeriesAMember
2021-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-12-31
0001589150
us-gaap:CommonStockMember
2021-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001589150
us-gaap:RetainedEarningsMember
2021-12-31
0001589150
RGBP:ContributedCapitalMember
2021-12-31
0001589150
2021-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2020-10-01
2020-12-31
0001589150
us-gaap:CommonStockMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2020-10-01
2020-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-10-01
2020-12-31
0001589150
us-gaap:RetainedEarningsMember
2020-10-01
2020-12-31
0001589150
RGBP:ContributedCapitalMember
2020-10-01
2020-12-31
0001589150
2020-10-01
2020-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-01-01
2021-03-31
0001589150
us-gaap:CommonStockMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-01-01
2021-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-03-31
0001589150
us-gaap:RetainedEarningsMember
2021-01-01
2021-03-31
0001589150
RGBP:ContributedCapitalMember
2021-01-01
2021-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-10-01
2021-12-31
0001589150
us-gaap:CommonStockMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-10-01
2021-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-10-01
2021-12-31
0001589150
us-gaap:RetainedEarningsMember
2021-10-01
2021-12-31
0001589150
RGBP:ContributedCapitalMember
2021-10-01
2021-12-31
0001589150
2021-10-01
2021-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2022-01-01
2022-03-31
0001589150
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2022-01-01
2022-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001589150
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001589150
RGBP:ContributedCapitalMember
2022-01-01
2022-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-03-31
0001589150
us-gaap:CommonStockMember
2021-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001589150
us-gaap:RetainedEarningsMember
2021-03-31
0001589150
RGBP:ContributedCapitalMember
2021-03-31
0001589150
2021-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2022-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2022-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2022-03-31
0001589150
us-gaap:CommonStockMember
2022-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2022-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001589150
us-gaap:RetainedEarningsMember
2022-03-31
0001589150
RGBP:ContributedCapitalMember
2022-03-31
0001589150
srt:MinimumMember
2021-10-01
2022-03-31
0001589150
srt:MaximumMember
2021-10-01
2022-03-31
0001589150
RGBP:ZanderTherapeuticsMember
2022-03-31
0001589150
2012-04-24
2022-03-31
0001589150
RGBP:DavidKoosMember
2022-03-31
0001589150
RGBP:DavidKoosMember
2022-03-31
0001589150
RGBP:DavidKoosMember
2021-10-01
2022-03-31
0001589150
RGBP:March82016Member
2022-03-31
0001589150
RGBP:April62016Member
2022-03-31
0001589150
RGBP:October312016Member
2022-03-31
0001589150
RGBP:October3120161Member
2022-03-31
0001589150
RGBP:October3120162Member
2022-03-31
0001589150
RGBP:March132017Member
2022-03-31
0001589150
RGBP:March132017Member
2021-10-01
2022-03-31
0001589150
RGBP:March312017Member
2022-03-31
0001589150
RGBP:March3120171Member
2022-03-31
0001589150
RGBP:March3120171Member
2021-10-01
2022-03-31
0001589150
RGBP:April192017Member
2022-03-31
0001589150
RGBP:May52017Member
2022-03-31
0001589150
RGBP:May52017Member
2021-10-01
2022-03-31
0001589150
RGBP:June262017Member
2022-03-31
0001589150
RGBP:June262017Member
2021-10-01
2022-03-31
0001589150
RGBP:Sept252017Member
2022-03-31
0001589150
RGBP:Sept252017Member
2021-10-01
2022-03-31
0001589150
RGBP:Oct0317Member
2022-03-31
0001589150
RGBP:Oct0317Member
2021-10-01
2022-03-31
0001589150
RGBP:Oct1617Member
2022-03-31
0001589150
RGBP:Oct1617Member
2021-10-01
2022-03-31
0001589150
RGBP:Nov0117Member
2022-03-31
0001589150
RGBP:Nov0117Member
2021-10-01
2022-03-31
0001589150
RGBP:Nov0120172Member
2022-03-31
0001589150
RGBP:Nov0120172Member
2021-10-01
2022-03-31
0001589150
RGBP:Dec2017Member
2022-03-31
0001589150
RGBP:Dec2017Member
2021-10-01
2022-03-31
0001589150
RGBP:Feb2818Member
2022-03-31
0001589150
RGBP:Feb2818Member
2021-10-01
2022-03-31
0001589150
RGBP:July112018Member
2022-03-31
0001589150
RGBP:July112018Member
2021-10-01
2022-03-31
0001589150
RGBP:September302018Member
2022-03-31
0001589150
RGBP:September302018Member
2021-10-01
2022-03-31
0001589150
RGBP:July192019Member
2022-03-31
0001589150
RGBP:September172021Member
2022-03-31
0001589150
RGBP:September172021Member
2021-10-01
2022-03-31
0001589150
RGBP:March172022Member
2022-03-31
0001589150
RGBP:ZanderTherapeuticsMember
2019-05-30
2019-06-11
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2019-11-01
2019-11-29
0001589150
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-03-31
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-03-31
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2022-03-31
0001589150
us-gaap:CommonStockMember
RGBP:ZanderTherapeuticsMember
2022-03-31
0001589150
us-gaap:CommonStockMember
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-03-31
0001589150
RGBP:UnrelatedPartyMember
2021-04-01
2021-06-30
0001589150
RGBP:UnrelatedPartyMember
2021-07-01
2021-09-30
0001589150
us-gaap:CommonStockMember
2022-03-31
0001589150
us-gaap:CommonStockMember
RGBP:OncologyPharmaMember
2022-03-31
0001589150
us-gaap:CommonStockMember
RGBP:OncologyPharmaMember
2021-10-01
2022-03-31
0001589150
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-03-01
2022-03-28
0001589150
us-gaap:SubsequentEventMember
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-04-01
2022-04-04
0001589150
us-gaap:SubsequentEventMember
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-04-01
2022-04-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 10-Q
☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended March 31, 2022
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from
Commission
File No. 333-191725
REGEN BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
Nevada |
45-5192997 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
4700 Spring Street, St 304, La Mesa, California 91942
(Address
of Principal Executive Offices)
619 722-5505
(Issuer’s
telephone number)
None
(Former
name, address and fiscal year, if changed since last report)
Check
whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12
months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes
☒ No
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☐
No ☒
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated
filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
☐ Large accelerated filer |
☐ Accelerated filer |
☐ Non-accelerated filer |
☒ Smaller reporting company |
|
☐ Emerging Growth Company |
APPLICABLE
ONLY TO CORPORATE ISSUERS:
As
of April 7, 2022 Regen Biopharma, Inc. had 4,736,002,832 common shares outstanding.
As
of April 7,2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.
As
of April 7, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.
As
of April 7, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.
As
of April 7, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
Yes
☐ No ☒
PART
I - FINANCIAL INFORMATION
Item
1. - Financial Statements